• Value-based healthcare and Value Labs

    Learn in this In Vivo article how a proposed new approach to value-based contracts could help drive the shift to value-based reimbursements and drug pricing.

  • Life sciences dealmaking expected to continue

    Our Global Capital Confidence Barometer shows that policy reform and portfolio rationalization have heightened dealmaking activity across the life sciences spectrum.

  • Participatory health

    Participatory health is transforming the healthcare industry. We examine shifts in emphasis, direction and focus necessary to realise a new and disruptive paradigm.

  • Australia’s diverted profits tax

    The centralization of intellectual property and functions into regional or global hubs is one of the main drivers of efficiency for life sciences multinational enterprises.

  • Cracking the engaged aging code through technology

    A convergence of technological advancements and trends are already underway that could help make the concept of "healthy aging" a reality.

  • Global Corporate Divestment Study: Life sciences

    How can life sciences companies generate a higher price for divestments and use them to fund growth opportunities? Learn more.

  • The 2017 outlook for life sciences

    Pressure on drug pricing, shifting political forces in key markets and potential tax relief in the US support a positive outlook for 2017 life sciences M&A.

  • It’s time to bring drug pricing down

    President Trump himself has said that it’s time to bring drug prices down. Within the industry, some are calling for self-regulation and greater transparency.

  • SEC comments and trends: Life sciences

    Insights into the SEC staff’s areas of focus, based on our analysis of current reporting issues found in filings for public life sciences companies.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:


  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

    We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

    We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

    So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

    Take a closer look:

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

    Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

    Take a closer look:

  • Medical technology

    Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

    Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

    Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

    From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

    Take a closer look:



Connect with us

Stay connected with us through social media, email alerts or webcasts.

EY-Applying IFRS 10 and IFRS 11

Applying IFRS 10 and IFRS 11

How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.